Safety and antitumor activity of the first-in-class EGFR-HER3 bispecific antibody-drug conjugate iza-bren (BL-B01D1) in patients with pretreated locally advanced or metastatic breast cancer: a phase 1b study.

izalontamab brengitecan (BL-B01D1) - Sichuan Biokin Pharmaceutical, BMS, Systimmune

http://www.ncbi.nlm.nih.gov/pubmed/42727637

C Wang; F Xu; G Jin; H Zhou; H Zhu; J Cui; J Wu; J Zhang; K Wang; M Sun; Q Wen; S Xiao; T Sun; W Chen; W Xie; X Wang; Y Chen; Y Du; Y Meng; Y Shi; Y Sun; Y Wang; Y Zhu; Z Wang; Z Zhuang

Sep 12, 2026